Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 26, Issue 12, 2007, Pages 907-914

  Horn, D ^a   Neofytos, D ^a   Fishman, J ^b   Steinbach, W ^c   Anaisie, E ^d   Marr, K A ^e,g   Pfaller, M ^f   Olyaei, A ^g  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF IOWA HEALTH CARE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; FEMALE; FUNGAL STRAIN; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDIASIS; DATABASES, FACTUAL; FUNGEMIA; GUIDELINE ADHERENCE; HUMANS; QUALITY OF HEALTH CARE;

EID: 35948979252     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-007-0383-4     Document Type: Article

References (15)

1. Marr KA (2004) Invasive Candida infections: the changing epidemiology. Oncology 18:9-14
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642-2645
3. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE et al (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 30:662-678
4. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161-189
5. Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366:1435-1442
6. Mora-Duarte J, Betts R, Rotstein C, Colombo AL et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020-2029
7. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
8. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239-244
9. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309-317
10. Patel M, Kunz DF, Trivedi VM, Jones MG, Moser SA, Baddley JW (2005) Initial management of candidemia at an academic medical center: evaluation of the IDSA guidelines. Diagn Microbiol Infect Dis 52:29-34
11. Reboli ARC, Pappas P et al (2005) Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis. In: Programs Abstr 45th Interscience Conf Antimicrobial Agents Chemotherapy. Washington D.C.
12. Pfizer (2006) Eraxis (anidulafungin) for injection. http://www.pfizer. com/pfizer/download/uspi_eraxis.pdf
13. Ruhnke MAKE, Chetchotisakd P et al (2005) Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. In: Programs Abstr 45th Interscience Conf Antimicrobial Agents Chemotherapy. Washington D.C.
14. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37:1172-1177
15. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232-1239